Company Filing History:
Years Active: 2019-2022
Title: The Innovations of Jean Da Silva Correia: Pioneering Advances in Immunology
Introduction
Jean Da Silva Correia is an accomplished inventor based in San Diego, CA, USA. He holds two patents that demonstrate his significant contributions to the field of immunology. His work primarily focuses on the development of antibodies targeting T cell immunoglobulin and mucin protein 3 (TIM-3), paving the way for new therapeutic interventions.
Latest Patents
Jean’s latest patents include a groundbreaking invention involving isolated immunoglobulin heavy chain polypeptides and light chain polypeptides that bind to the TIM-3 protein. These inventions provide innovative TIM-3-binding agents that are crucial for the development of treatments aimed at various disorders. The applications of these inventions extend to the treatment of cancer, infectious diseases, and autoimmune diseases, offering promising solutions to critical health challenges.
Career Highlights
Jean Da Silva Correia is a prominent inventor associated with Anaptysbio, Inc., a company known for its innovative work in the realm of immunotherapies. His two patents underscore his dedication and intellectual contribution to advancing medical science and improving patients' lives through targeted therapies.
Collaborations
Throughout his career, Jean has collaborated with esteemed professionals in the field, including coworkers like Marilyn Kehry and David J King. These partnerships have propelled his research forward, resulting in the development of cutting-edge immunotherapies that hold potential for numerous clinical applications.
Conclusion
With a solid background in developing TIM-3-targeted antibodies, Jean Da Silva Correia continues to be an influential figure in immunology. His patents not only highlight his inventive spirit but also represent significant advancements in treatment options for various serious health conditions. Jean's contributions reflect the synergy of innovation and collaboration, leading to impactful changes in the medical landscape.